NCT06810869View on ClinicalTrials.gov

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

November 17, 2026

Study Completion Date

November 17, 2026

Conditions
Stable Vitiligo
Interventions
DRUG

human induced pluripotent stem cell derived exosomes （GD-iExo-003）

human induced pluripotent stem cell derived exosomes （GD-iExo-003）

DRUG

a placebo of exosomes derived from human induced pluripotent stem cell for injection

a placebo of exosomes derived from human induced pluripotent stem cell for injection

Trial Locations (1)

241000

The Second Affiliated Hospital of Wannan Medical College, Wuhu

Sponsors

Collaborators (1)

Guidon Pharmaceutics Ltd.
All Listed Sponsors
collaborator

Guidon Pharmaceutics Ltd.

INDUSTRY

lead

Second Affiliated Hospital of Wannan Medical College

OTHER